

# Association of the FAM46A gene VNTRs and BAG6 rs3117582 SNP with non small cell lung cancer (NSCLC) in Croatian and Norwegian populations

---

Etokebe, Godfrey Essien; Zienolddiny, Shanbeh; Kupanovac, Željko; Balen, Sanja; Flego, Veljko; Bulat-Kardum, Ljiljana; Radojčić-Badovinac, Anđelka; Skaug, Vidar; Bakke, Per; Haugen, Aage; ...

Source / Izvornik: PLoS ONE, 2015, 10

Journal article, Published version

Rad u časopisu, Objavljena verzija rada (izdavačev PDF)

<https://doi.org/10.1371/journal.pone.0122651>

Permanent link / Trajna poveznica: <https://um.nsk.hr/um:nbn:hr:184:004334>

Rights / Prava: [In copyright](#)/Zaštićeno autorskim pravom.

Download date / Datum preuzimanja: 2025-01-15



Repository / Repozitorij:

[Repository of the University of Rijeka, Faculty of Medicine - FMRI Repository](#)



## Association of the *FAM46A* Gene VNTRs and *BAG6* rs3117582 SNP with Non Small Cell Lung Cancer (NSCLC) in Croatian and Norwegian Populations

Godfrey Essien Etokebe, Shanbeh Zienolddiny, Zeljko Kupanovac, Morten Enersen, Sanja Balen, Veljko Flego, Ljiljana Bulat-Kardum, Anđelka Radojčić-Badovinac, Vidar Skaug, Per Bakke, Aage Haugen, Zlatko Dembic

Published: April 17, 2015 • <https://doi.org/10.1371/journal.pone.0122651>

### Abstract

We analyzed for associations between a variable number of tandem repeat (VNTR) polymorphism in the Family with sequence similarity 46, member A (*FAM46A*) gene and a single nucleotide polymorphism (rs3117582) in the BCL2-Associated Athanogene 6 (*BAG6*) with non small cell lung cancer in Croatian and Norwegian subjects. A total of 503 (262 Croatian and 241 Norwegian) non small cell lung cancer patients and 897 controls (568 Croatian and 329 Norwegian) were analyzed. We found that the frequency of allele b (three VNTR repeats) of *FAM46A* gene was significantly increased in the patients compared to the healthy controls in the Croatian and the combined Croatian and Norwegian subjects. Genotype frequencies of cd (four and five VNTR repeats) and cc (four VNTR repeats homozygote) of the *FAM46A* gene were significantly decreased in the patients compared to the healthy controls in the Croatian and Norwegian subjects, respectively. Logistic regression analyses revealed *FAM46A* genotype cc to be an independent predictive factor for non small cell lung cancer risk in the Norwegian subjects after adjustment for age, gender and smoking status. This is the first study to suggest an association between the *FAM46A* gene VNTR polymorphisms and non small cell lung cancer. We found also that *BAG6* rs3117582 SNP was associated with non small cell lung cancer in the Norwegian subjects and the combined Croatian-Norwegian subjects corroborating the earlier finding that *BAG6* rs3117582 SNP was associated with lung cancer in Europeans. Logistic regression analyses revealed that genotypes and alleles of *BAG6* were independent predictive factor for non small cell lung cancer risk in the Norwegian and combined Croatian-Norwegian subjects, after adjustment for age and gender.

**Citation:** Etokebe GE, Zienolddiny S, Kupanovac Z, Enersen M, Balen S, Flego V, et al. (2015) Association of the *FAM46A* Gene VNTRs and *BAG6* rs3117582 SNP with Non Small Cell Lung Cancer (NSCLC) in Croatian and Norwegian Populations. PLoS ONE 10(4): e0122651. <https://doi.org/10.1371/journal.pone.0122651>

**Academic Editor:** Qing-Yi Wei, Duke Cancer Institute, UNITED STATES

**Received:** November 22, 2014; **Accepted:** February 11, 2015; **Published:** April 17, 2015

**Copyright:** © 2015 Etokebe et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

**Data Availability:** All relevant data are within the paper.

**Funding:** The authors have no support or funding to report.

**Competing interests:** The authors have declared that no competing interests exist.

### Introduction

Lung cancer is the most predominant cause of cancer death globally [1]. Through epidemiological studies many environmental risk factors have been established for lung cancer including smoking, air pollution and industrial substances [2]. Although tobacco smoking is the major risk factor, genetic factors also affect lung cancer susceptibility [3–5]. Direct evidence for genetic predisposition to lung cancer is highlighted by several genome wide association studies (GWAS) that has been done [6–11].

Most of the genetic association reports studying lung cancer use single nucleotide polymorphisms (SNPs) as markers. A genomic variant that is understudied is the variable number of tandem repeats (VNTR) probably due to VNTR complexity and the challenges in assaying them. These limitations do not favor the discovery of novel VNTRs as potential predictive and prognostic factors in lung cancer etiology. Predictive and prognostic factors are important in the diagnosis and treatment of lung cancer [12–14]. The positive long term economic impact of robustly testing for predictive factors cannot be underestimated. This enhances the quality of medical care by significantly reducing false positives or negatives that may impact negatively on the treatment outcome. For example, robust testing for epidermal growth factor receptor (*EGFR*) gene mutational status in non small cell lung cancer (NSCLC) patients has defined this gene as an important predictive and prognostic factor in NSCLC diagnosis and treatment. This has also allowed for the therapeutic targeting of this genetic locus in NSCLC treatment [15;16].

VNTRs can modulate many biological processes such as gene transcription and protein function. They may also be responsible for many disorders in humans that include unstable (genetic) repeat expansions [17;18]. There are few reports on the association between VNTRs and lung cancer susceptibility in case-control studies. These include VNTRs in the *H-ras* gene [19;20], interleukin-1 receptor antagonist gene (*IL1RN* \*2) [21;22] and Mitogen-activated protein kinase 2 gene (*MAPKAPK2*) [23].

The Family-with-sequence-similarity 46, member A (*FAM46A*) gene [24] is located at chromosome 6.14.1. It harbors a VNTR within its coding sequence in exon 2. This VNTR may vary from two to seven repeats per chromosome [25;26]. The *FAM46A* polypeptide chain also contains the Domain of unknown function 1693 (DUF 1693) [27] and as such no biological role has been assigned to the *FAM46A* gene as of date [28;29]. *FAM46A* protein interacts with the *BCL2*-Associated Athanogene 6 (*BAG6*) protein [28] which has been reported to modify risk of lung cancer [30]. The *BAG6* gene is located on chromosome 6p21.3 and regulated apoptosis and HSP70 [31]. *FAM46A* protein also interacts with the zinc finger, FYVE domain-containing 9 (*ZFYVE9*) protein [28] which is involved in *TGF-β* signaling.

We previously reported that the mouse homologue of the *Fam46a* gene is expressed in developing tooth buds. Due to its nuclear localization and interaction with the human transcription factor, *ZFYVE9* protein, we suggested that the *FAM46A* protein might be involved in cellular proliferation [32]. In addition, we have recently reported that the *FAM46A* gene VNTR is associated with increased risk of tuberculosis and osteoarthritis [33;34]. Data suggest that patients with tuberculosis are associated with increased lung cancer [35]. Based on these facts, we hypothesized that the *FAM46A* gene may be involved in lung cancer and that this involvement may be through variations in the length of the *FAM46A* VNTR. In addition, we analyzed for the association of a *BAG6* SNP to validate its previous reported association with lung cancer [30]. The associations were investigated in two different European populations.

## Materials and Methods

### Ethics Statement

The study was approved by the Medical ethics committees of the University Hospital, University of Rijeka, Croatia, and Regional Committees for Medical and Health Research Ethics, Oslo, Norway. Written consents were obtained from all participants.

### Subjects

The number of participants, sex and age distribution of the subjects are described in Table 1 for the both the Croatian and Norwegian subjects, respectively. Blood samples were collected at the Clinical Institute for Transfusion Medicine, University Hospital Center Rijeka, Rijeka, Croatia for the Croatian subjects and at National Institute of Occupational Health, Oslo, Norway for the Norwegian subjects. Ethnicity of participants was established by patient or healthy individual interview and by consulting the admission documentation at the hospitals. Some clinical information for particularly subjects was lacking and as such, not all subjects were included in the characteristics estimations in Table 1. Subjects were not matched for possible confounding factors such as age, gender, and smoking status. Not all patients and controls were typed for the two markers due to lack of particular samples.

Subjects	Characteristic	Patients	Controls	p-value
Croatians	n <sup>a</sup>	219	473	
	Average age (male and female)	66.12 (±10.38)	42.83 (±10.84)	<0.001
	Age range (male and female)	31–92	19–73	
	n <sup>b</sup>	57	149	
	Average age (female)	66.33 (±10.99)	43.12 (±10.89)	<0.001
	Age range (female)	42–96	21–96	
	n <sup>c</sup>	159	282	
	Average age (male)	66.02 (±10.14)	41.91 (±10.52)	<0.001
	Age range (male)	31–92	19–73	
	Smoking status	never: 97 ever: 225	never: 94 ever: 188	
Histology	Adenocarcinoma: 87			
	Squamous carcinoma: 113			
	Large cell carcinoma: 3			
	undetermined NSCLC: 79			
Norwegians	n <sup>a</sup>	298	292	
	Average age (male and female)	64.24 (±10.22)	58.05 (±10.24)	<0.001
	Age range (male and female)	25–92	45–96	
	n <sup>b</sup>	79	69	
	Average age (female)	64.54 (±10.43)	61.53 (±10.36)	0.19
	Age range (female)	36–81	43–83	
	n <sup>c</sup>	197	282	
	Average age (male)	64.45 (±10.14)	59.06 (±10.26)	<0.001
	Age range (male)	29–71	45–96	
	Smoking status	never: 17 ever: 279	never: 21 ever: 282	<0.001
Histology	Adenocarcinoma: 148			
	Squamous carcinoma: 98			
	Large cell carcinoma: 34			
	undetermined NSCLC: 16			
Paired Croatian and Norwegian	n <sup>a</sup>	693	760	
	Average age (male and female)	65.13 (±10.14)	49.29 (±10.16)	<0.001
	Age range (male and female)	31–96	19–96	
	n <sup>b</sup>	124	259	
	Average age (female)	65.16 (±10.14)	49.53 (±10.16)	<0.001
	Age range (female)	36–85	21–83	
	n <sup>c</sup>	369	562	
	Average age (male)	65.12 (±10.14)	49.17 (±10.07)	<0.001
	Age range (male)	29–92	19–96	
	Smoking status	never: 54 ever: 434	never: 43 ever: 76	
Histology	Adenocarcinoma: 215			
	Squamous carcinoma: 211			
	Large cell carcinoma: 37			
	undetermined NSCLC: 79			

**Table 1. Characteristics of non small cell lung cancer (NSCLC) patients and normal (healthy) controls.**

<https://doi.org/10.1371/journal.pone.0122651.t001>

### Genomic DNA extraction

Genomic DNA from NSCLC patients and healthy controls was extracted from whole blood as described previously [36–38]. In brief, 200 µl of whole blood was mixed with 400 µl of sucrose buffer (0.32 M sucrose, 10 mM Tris-HCl, pH 7.5, 5 mM MgCl<sub>2</sub>, 1%, v/v, Triton X-100) and incubated for 1 min at room temperature. To collect white cell nuclei, samples were centrifuged 2 min at 5,000g. Precipitated nuclei were washed twice with 800 µl of sucrose buffer and centrifuged (2 min at 5,000g). After the second wash, the nuclei were re-suspended in 400 µl DNAzol (Invitrogen Corporation, Carlsbad, CA, USA) and incubated at room temperature for 5 min. Genomic DNA was precipitated with 200 µl of 100% ethanol and collected by centrifugation (2 min at 5,000g). The precipitate was washed with 1 ml of 75% ethanol and centrifuged for 1 min at 5,000g, twice. Genomic DNA was re-suspended in Tris-EDTA buffer solution (10 mM Tris-HCl, 1 mM disodium EDTA, pH 8.0; Sigma-Aldrich Chemie GmbH, Munich, Germany).

### Genotyping by DNA-sequencing Capillary Electrophoresis

DNA fragments of 647 base pairs (bp) in length encoding the *FAM46A* gene were amplified from human genomic DNA by using a FAM-labeled forward primer, designated Gfam\_VNF (5'-AGGGTACTTCGCCATGTCTG-3'), in combination with an unlabeled reverse primer, designated GEX\_R (5'-CTCGTGATGGCCACAGATT-3'), by PCR as previously described [33;34]. The 25 µL total volume PCR mixtures contained the following: 25 ng of genomic DNA, 0.2 µM each of the specific primers, and 1x Paq5000 Hotstart PCR master mix (Agilent Technologies, Inc., CA, USA). PCR was performed in a Peltier Thermal cycler (MJ Research, Massachusetts, USA). The Paq5000 polymerase was activated by an initial step at 95°C lasting 2 min, followed by 35 cycles of denaturing, annealing, and extension steps at 95°C for 20 s, 65°C for 20 s, and 72°C for 30 s, respectively, followed by a final extension step at

72°C for 5 min. Amplicons were resolved by 1% ethidium bromide-stained agarose gel electrophoresis and visualized by the Geldoc imaging system (Bio-Rad, Hercules, CA, USA). Amplicons (0.5 µl) were mixed with 0.5 µl GeneScan 1200 LIZ Size Standard (Life Technologies, NY, USA) and loaded onto a 3730 DNA Analyzer (Life Technologies, NY, USA) for allele separation. Separated alleles were analyzed by the Genemapper software (Life Technologies, NY, USA). Allele (VNTR) identity was confirmed by sequencing directly PCR amplicons from samples that were genotyped as various homozygotes (two each). To further confirm the genotyping results, 10% of the samples were re-genotyped with 100% concordance. Also, randomly selected samples that were genotyped as heterozygotes were sub-cloned into TOPO Zero Blunt Sequencing plasmids (Life Technologies, NY, USA) prior to sequencing. Sequencing reaction was performed using the BigDye chemistry 3.1 (Life Technologies, NY, USA) with forward and reverse primers GVF (5'-AGGGTACTTCGCCATGTCTG-3') and GEX\_R (5'-CTCGTGATGGCCACAGATT-3'), respectively and resolved by the ABI 3730 DNA analyzer (Life Technologies, NY, USA).

#### Genotyping of BAG6 rs3117582 Single Nucleotide Polymorphism (SNP)

BCL2-Associated Athanogene 6 (BAG6) gene rs3117582 SNP was assessed by probe-based real-time PCR assays as described by the Kits manufacturer (Life Technologies, NY, USA) in our NSCLC patient and control groups, respectively. Stratagene MX3005 real-time PCR cyler was applied (Agilent Technologies, Santa Clara, CA, USA) for temperature cycling and signal quantification.

#### Statistical analysis

The differences in the distribution of categorical variables, including demographic characteristics, selected variables, allelic and genotypic frequencies were analyzed by the chi-square (Fisher two tailed) method using the 2-way Contingency Table Analysis (available at <http://statpages.org/ctab2x2.html> and <http://research.microsoft.com/en-us/um/redmond/projects/mscompbio/fisherexacttest/>) or t-test (<http://www.graphpad.com/quickcalcs/ttest1/?Format=SD>) between patients and controls. The Hardy-Weinberg analysis was done using the Arlequin software version 3.5 (Genetics and Biometry Laboratory, University of Geneva, Geneva, Switzerland), which showed that the FAM46A VNTRs and the BAG6 genotypes were in Hardy-Weinberg equilibrium (HWE). A statistically significant difference was defined when p was ≤0.05. The associations between the FAM46A VNTRs and BAG6 rs3117582 SNP polymorphisms and non small cell lung cancer risk were estimated by computing the odds ratios (ORs) and their 95% confidence intervals (CIs). We performed logistic regression analysis to evaluate the influence of age, gender and smoking status as confounders for the association of FAM46A VNTRs and BAG6 rs3117582SNP, respectively, with non small cell lung cancers in the Croatian and Norwegian subjects. Smoking status could not be included as a cofounder when we analyzed for the association of these genetic elements with non small cell lung cancer in the Croatian subjects and the combined Croatian-Norwegian subjects because information on the smoking status of the Croatian healthy control group was not available. Logistic regression analyses were carried out using SPSS (version 21; SPSS Inc., Chicago, IL, USA) and a p-value of ≤ 0.05 was set as the criterion for statistical significance.

## Results

#### Allelic and genotypic frequencies of the FAM46A gene VNTR

The frequency of VNTR genotypes and alleles for the FAM46A gene in the patients and healthy controls are listed in Table 2 and 3. We found twenty genotypes comprising of six alleles for the FAM46A gene with different frequencies in the two populations. Therefore, in further analyses of genotypes we chose to analyze results separately for each population, in addition to performing combined analyses. Analysis of the allelic frequencies, however, showed that the VNTR with 5 repeats (d allele in Table 3) was the most frequent allele with a similar frequency in healthy controls in both the Croatian (42%) and Norwegian (40%) populations. We chose, therefore, d allele as the reference allele in further analysis of the odds ratios. Tables 4 and 5 show the risk for lung cancer associated with each genotype (Table 4) or allele (Table 5) comparing frequencies of each genotype or allele in cases and controls with the most frequent genotype or allele as reference. In the Croatian subjects the cd genotype and in the Norwegian subjects the cc genotype was associated with a reduced risk of lung cancer, whereas combining both groups only cc genotype had a significant effect on reduction of the cancer risk (Table 4). Regarding allele frequencies, only subjects with a b allele in the Croatian population had a significant increased risk of lung cancer (Table 5).

Subjects	Variant	VNTR	Genotype frequency	
			Patients (n = 302) frequency (%)	Controls (n = 308) frequency (%)
Croatians	Genotype			
	bc	3/3	24 (0.08)	36 (0.08)
	cd	4/4	19 (0.07)	31 (0.05)
	bd	5/6	40 (0.13)	50 (0.16)
	ac	6/8	2 (0.01)	3 (0.01)
	bc	7/7	0	1 (0.00)
	ad	2/3	0	4 (0.01)
	ac	3/4	0	1 (0.00)
	ad	2/5	4 (0.02)	4 (0.01)
	ac	2/6	0	2 (0.00)
Norwegians	Genotype			
	bc	2/7	0	1 (0.00)
	bd	3/4	38 (0.10)	63 (0.11)
	bd	3/5	40 (0.20)	120 (0.20)
	bd	3/6	9 (0.03)	20 (0.04)
	cd	3/7	1 (0.00)	5 (0.01)
	cd	4/6	34 (0.13)	119 (0.20)
	cd	4/8	9 (0.03)	18 (0.03)
	cd	4/7	1 (0.00)	0
	cd	5/6	12 (0.04)	39 (0.07)
Norwegians	Genotype			
	bc	3/3	10 (0.04)	21 (0.06)
	cd	4/4	9 (0.04)	36 (0.12)
	bd	5/5	50 (0.21)	66 (0.20)
	ac	6/6	0	2 (0.01)
	ad	2/3	1 (0.00)	2 (0.01)
	bc	2/4	0	2 (0.01)
	ad	2/5	1 (0.00)	4 (0.01)
	ac	2/6	0	2 (0.01)
	bd	3/4	27 (0.10)	40 (0.12)
bd	3/5	46 (0.16)	160 (0.16)	
bd	3/6	12 (0.04)	10 (0.03)	
cd	4/6	47 (0.20)	98 (0.17)	
cd	4/8	7 (0.03)	11 (0.03)	
cd	4/7	1 (0.00)	1 (0.00)	
cd	5/6	12 (0.04)	27 (0.08)	
cd	5/7	1 (0.00)	1 (0.00)	
cd	6/7	1 (0.00)	0	

n: frequency of genotypes/alleles per group; n: total number of alleles per group

doi:10.1371/journal.pone.0122651.t002

**Table 2. Genotypes frequencies of FAM46A VNTR polymorphisms in Croatian and Norwegian subjects with NSCLC and healthy controls.**  
<https://doi.org/10.1371/journal.pone.0122651.t002>

Subjects	Variant		Allele frequency	
	Allele	VNTR	Patients (n = 524) frequency (%)	Controls (n = 1326) frequency (%)
Croatians	a	2	4 (0.81)	11 (0.83)
	b	3	105 (20.21)	209 (20.25)
	c	4	129 (24.62)	258 (20.25)
	d	4	199 (38.36)	477 (36.42)
	e	6	39 (7.46)	94 (7.09)
	f	7	2 (0.38)	12 (0.91)
	f	7	2 (0.38)	12 (0.91)
Norwegians	a	2	2 (0.54)	10 (0.83)
	b	3	124 (30.26)	144 (23.25)
	c	4	110 (27.92)	162 (26.96)
	d	4	208 (52.42)	288 (46.42)
	e	6	20 (5.07)	54 (8.98)
	f	7	3 (0.76)	2 (0.33)
	f	7	3 (0.76)	2 (0.33)
Combined Croatians and Norwegians	a	2	6 (0.91)	21 (0.83)
	b	3	209 (29.29)	453 (25.25)
	c	4	239 (33.78)	420 (23.46)
	d	4	407 (56.40)	763 (41.41)
	e	6	59 (8.27)	138 (7.66)
	f	7	5 (0.70)	14 (0.81)
	f	7	5 (0.70)	14 (0.81)

N: frequency of genotypes/alleles per group, n: total number of alleles per group  
doi:10.1371/journal.pone.0122651.t003

**Table 3. Alleles frequencies of FAM46A VNTR polymorphisms in Croatian and Norwegian subjects with NSCLC and healthy controls.**  
<https://doi.org/10.1371/journal.pone.0122651.t003>

Subjects	VNTR Variant	Unadjusted for covariates		Adjusted for covariates	
		Genotype	OR(95% CI), p, N = 830	Reference	OR(adjusted), 95% CI, p, N = 724
Croatians	Allele				
	a	1.03, 0.72-1.48, 0.39	Reference	1.26, 0.66-2.40, 0.48	
	b	1.36, 0.75-2.54, 0.31	1.06, 0.64-1.81, 0.76	1.48, 0.84-2.61, 0.17	
	c	0.96, 0.59-1.57, 0.77	0.97, 0.54-1.73, 0.94	0.97, 0.54-1.73, 0.94	
	d	1.20, 0.63-2.28, 0.58	1.44, 0.73-2.86, 0.31	1.44, 0.73-2.86, 0.31	
	e	0.48, 0.23-0.97, 0.037	0.48, 0.23-0.96, 0.038	0.48, 0.23-0.96, 0.038	
	f	1.30, 0.43-3.82, 0.63	1.23, 0.43-3.52, 0.68	1.23, 0.43-3.52, 0.68	
	af	0.82, 0.30-2.22, 0.58	0.82, 0.31-2.21, 0.68	0.82, 0.31-2.21, 0.68	
	bf	0.80, 0.51-1.25, 0.33	0.84, 0.51-1.43, 0.53	0.84, 0.51-1.43, 0.53	
	LFG	0.51, 0.76-0.68	0.53, 0.21-1.43, 0.22	0.53, 0.21-1.43, 0.22	
Norwegians	Allele				
	a	0.92, 0.41-1.98, 0.83	Reference	0.98, 0.44-2.18, 0.98	
	b	1.30, 0.74-2.34, 0.39	1.18, 0.62-2.18, 0.65	1.18, 0.62-2.18, 0.65	
	c	1.06, 0.63-1.77, 0.77	0.97, 0.54-1.73, 0.94	0.97, 0.54-1.73, 0.94	
	d	1.26, 0.59-3.05, 0.64	1.23, 0.60-2.46, 0.52	1.23, 0.60-2.46, 0.52	
	e	0.37, 0.14-0.98, 0.02	0.37, 0.14-0.98, 0.02	0.37, 0.14-0.98, 0.02	
	f	1.11, 0.44-1.89, 0.76	1.03, 0.59-1.84, 0.94	1.03, 0.59-1.84, 0.94	
	af	0.81, 0.28-2.25, 0.68	0.77, 0.27-2.22, 0.63	0.77, 0.27-2.22, 0.63	
	bf	0.73, 0.24-1.92, 0.61	0.73, 0.24-1.92, 0.61	0.73, 0.24-1.92, 0.61	
	LFG	1.08, 0.48-2.51, 0.86	1.14, 0.47-2.75, 0.78	1.14, 0.47-2.75, 0.78	
Combined Croatians and Norwegians	Allele				
	a	1.06, 0.59-1.91, 0.83	Reference	1.27, 0.71-2.28, 0.43	
	b	1.30, 0.74-2.34, 0.39	1.27, 0.71-2.28, 0.43	1.27, 0.71-2.28, 0.43	
	c	1.06, 0.63-1.77, 0.77	0.97, 0.54-1.73, 0.94	0.97, 0.54-1.73, 0.94	
	d	1.26, 0.59-3.05, 0.64	1.23, 0.60-2.46, 0.52	1.23, 0.60-2.46, 0.52	
	e	0.37, 0.14-0.98, 0.02	0.37, 0.14-0.98, 0.02	0.37, 0.14-0.98, 0.02	
	f	1.11, 0.44-1.89, 0.76	1.03, 0.59-1.84, 0.94	1.03, 0.59-1.84, 0.94	
	af	0.81, 0.28-2.25, 0.68	0.77, 0.27-2.22, 0.63	0.77, 0.27-2.22, 0.63	
	bf	0.73, 0.24-1.92, 0.61	0.73, 0.24-1.92, 0.61	0.73, 0.24-1.92, 0.61	
	LFG	0.88, 0.50-1.54, 0.66	1.08, 0.50-2.12, 0.89	1.08, 0.50-2.12, 0.89	

p<sup>U</sup>: unadjusted p-value.  
p<sup>G</sup>: p-value adjusted for gender.  
p<sup>AG</sup>: p-value adjusted for age and gender.  
p<sup>AGS</sup>: p-value adjusted for age, gender and smoking status.  
N: number of alleles or genotypes include in the analysis. LFG: Low frequency genotypes (alleles) are not included in the analysis. CI: confidence interval. OR: Odds ratio.  
doi:10.1371/journal.pone.0122651.t004

**Table 4. Association of FAM46A VNTR genotypes with NSCLC in Croatian and Norwegian subjects.**  
<https://doi.org/10.1371/journal.pone.0122651.t004>

Subjects	VNTR Variant	Unadjusted for covariates		Adjusted for covariates	
		Allele	OR(95% CI), p, N = 1660	Reference	OR(adjusted), 95% CI, p, N = 1468
Croatians	a				
	d		Reference		
	a	0.87, 0.27-2.77, 0.82	0.85, 0.23-3.15, 0.81		
	b	1.32, 1.03-1.70, 0.03	1.32, 1.003-1.74, 0.048		
	c	1.14, 0.87-1.49, 0.36	1.18, 0.88-1.59, 0.27		
	e	0.97, 0.63-1.49, 0.89	0.99, 0.64-1.46, 0.94		
	f	0.40, 0.09-1.80, 0.23	0.44, 0.10-2.02, 0.29		
Norwegians	a				
	d		Reference		
	a	0.25, 0.06-1.17, 0.08	0.32, 0.07-1.52, 0.15		
	b	1.09, 0.81-1.47, 0.58	1.07, 0.78-1.48, 0.68		
	c	0.76, 0.56-1.02, 0.07	0.75, 0.54-1.04, 0.08		
	e	0.82, 0.52-1.30, 0.40	0.80, 0.49-1.31, 0.37		
	f	1.90, 0.31-11.44, 0.49	1.80, 0.31-11.76, 0.49		
Combined Croatians and Norwegians	a				
	d		Reference		
	a	0.52, 0.21-1.30, 0.16	0.53, 0.17-1.65, 0.28		
	b	1.19, 0.99-1.44, 0.07	1.20, 0.94-1.53, 0.15		
	c	0.97, 0.79-1.18, 0.78	0.91, 0.71-1.16, 0.49		
	e	0.90, 0.66-1.23, 0.51	0.84, 0.56-1.25, 0.39		
	f	0.65, 0.23-1.82, 0.42	0.68, 0.21-2.12, 0.76		

p<sup>U</sup>: unadjusted p-value.  
p<sup>G</sup>: p-value adjusted for gender.  
p<sup>AG</sup>: p-value adjusted for age and gender.  
p<sup>AGS</sup>: p-value adjusted for age, gender and smoking status.  
N: number of alleles or genotypes include in the analysis. CI: confidence interval. OR: Odds ratio.  
doi:10.1371/journal.pone.0122651.t005

**Table 5. Association of FAM46A VNTR alleles with NSCLC in Croatian and Norwegian subjects.**  
<https://doi.org/10.1371/journal.pone.0122651.t005>

**Genotypic and Allelic frequencies of BAG6 rs3117582 SNP**

For the BAG6 rs3117582 polymorphism we found a gene-dosage increased risk for lung cancer associated with the C allele of BAG6 rs3117582 SNP in the Norwegian subjects. The subjects carrying one C allele had 1.70-fold increased lung cancer risk and subjects with two variant alleles (CC) had almost 7-fold increased risk of lung cancer. No such association was present in the Croatian subjects; however, combining the subjects from both populations the associations remained significant and similar to the associations found in the Norwegian population (Table 6).



Subjects	SNP Variant	Number of cases (n)	Number of healthy controls (n)	Unadjusted for covariates	Adjusted for covariates
Croatians	Genotype	n = 262	n = 568	OR(95% CI), p <sup>††</sup>	OR(95% CI), p <sup>†††</sup>
	AA	218	491	Reference	Reference
	AC	47	89	1.34, 0.88–2.02, 0.17	1.48, 0.94–2.33, 0.09
	CC	6	6	1.15, 0.21–6.16, 0.88	1.58, 0.38–6.87, 0.61
Norwegians	Genotype	n = 249	n = 332	OR(95% CI), p <sup>††</sup>	OR(95% CI), p <sup>†††</sup>
	AA	175	271	Reference	Reference
	AC	62	96	1.78, 1.19–2.66, 0.01	1.68, 1.09–2.61, 0.02
	CC	8	3	4.26, 1.11–16.26, 0.03	7.06, 1.48–34.68, 0.01
Combined Croatians and Norwegians	Genotype	n = 498	n = 664	OR(95% CI), p <sup>††</sup>	OR(95% CI), p <sup>†††</sup>
	AA	393	542	Reference	Reference
	AC	134	116	1.76, 1.28–2.27, 0.0003	1.72, 1.27–2.35, 0.0005
	CC	16	6	4.26, 1.68–10.97, 0.003	6.88, 2.28–21.14, 0.0004
Croatians	Allele	n = 522	n = 1128	OR(95% CI), p <sup>††</sup>	OR(95% CI), p <sup>†††</sup>
	a	475	1050	Reference	Reference
	b	47	78	1.28, 0.91–1.84, 0.14	1.48, 0.99–2.22, 0.05
	c	6	6	1.15, 0.21–6.16, 0.88	1.58, 0.38–6.87, 0.61
Norwegians	Allele	n = 498	n = 664	OR(95% CI), p <sup>††</sup>	OR(95% CI), p <sup>†††</sup>
	a	343	542	Reference	Reference
	b	142	122	1.82, 1.28–2.62, 0.0002	1.68, 1.10–2.54, 0.0004
	c	13	6	4.26, 1.68–10.97, 0.003	6.88, 2.28–21.14, 0.0004
Combined Croatians and Norwegians	Allele	n = 1020	n = 1800	OR(95% CI), p <sup>††</sup>	OR(95% CI), p <sup>†††</sup>
	a	815	1592	Reference	Reference
	b	115	200	1.28, 0.91–1.84, 0.14	1.48, 0.99–2.22, 0.05
	c	17	6	1.15, 0.21–6.16, 0.88	1.58, 0.38–6.87, 0.61

**Table 6. Association of BAG6 SNP 3117582 with NSCLC in Croatian and Norwegian subjects.**

<https://doi.org/10.1371/journal.pone.0122651.t006>

## Discussion

The present study investigates the association between a VNTR in exon 2 of the *FAM46A* gene and a SNP (rs3117582) in the *BAG6* gene and risk of NSCLC in two case-control studies from Croatia and Norway. We found that an allele of *FAM46A* gene that carries three VNTR repeats (designated as allele b) was associated with increased risk of lung cancer in the Croatian subjects. In addition, a genotype of *FAM46A* gene with 4 and 5 VNTR repeats (designated cd) was associated with reduced risk of cancer in these subjects. However, another genotype (cc) conferred reduced risk to lung cancer in the Norwegian subjects. To date, this is the first report of an association between the *FAM46A* gene and NSCLC.

Of particular interest is our observation that the cc and cd genotypes of the *FAM46A* gene confer reduced risk to NSCLC in the Norwegian and Croatian subjects, respectively. In addition, we found that the *FAM46A* bd and dd genotypes were the dominant genotypes in the Croatian and Norwegian subjects, respectively. These findings may suggest that the frequency of the dominant genotype of the *FAM46A* gene may influence the particular genotypes(s) that associates with NSCLC risk in each population. There is the possibility that these polymorphisms could be markers for susceptibility or reduced risk factor for example binding sites for miRNA, CpG methylation changes, SNPs in vicinity or genetic instability. Our results may therefore encourage further studies aimed at replicating our results, validating and/or eliminating the possibility of false positives or negatives that may be present in our results as a consequence of these genetic events.

The function of the *FAM46A* gene and its component domains (PS50315 and DUF1693) is unknown [25]. The DUF domain is present in many hypothetical proteins including nematode prion-like proteins [27] and in nucleotidyltransferase superfamily genes with unknown function [27]. Our results suggest that the VNTR-encoded PS50315 domain of the *FAM46A* protein might have functional importance in NSCLC. The *FAM46A* gene might have a role in *TGF-β* signaling, cell death (apoptosis) and/or inflammation due to its interaction with the *ZFYVE9* protein [28]. An experimentally determined interacting partner of the *FAM46A* protein is the *ZFYVE9* protein [28]. *ZFYVE9* protein is involved in the recruitment of unphosphorylated forms of *SMAD2/SMAD3* to the *TGF-β* receptor (*TGF-βR*) [39]. Phosphorylation of *SMAD2/SMAD3* induces dissociation from *ZFYVE9*. This allows for the formation of *SMAD2/SMAD4* complexes and the consequent translocation of the *SMAD2/SMAD4* complexes to the nucleus. Perhaps the *FAM46A* protein is involved in this cascade of events. *TGF-β* is a potent inhibitor of cell growth and accumulating evidence suggests that perturbation of *TGF-β* signaling pathway leads to tumorigenesis [40]. It is therefore tempting to speculate that *FAM46A* protein may be involved in lung cancer etiology through its participation in the *TGF-β* signaling pathway. This may involve the VNTR-encoded PS50315 domain of *FAM46A* gene. Our results may therefore encourage further studies to validate this postulation.

We found that the *BAG6* rs3117582 SNP is associated with NSCLC both at the genotypic and allelic levels in the Norwegian subjects and the combined Croatian and Norwegian subjects. This is interesting since *BAG6* protein is an interacting partner of *FAM46A* protein [28]. Previous reports have shown that SNPs in *BAG6* gene (rs1052486 and rs3117582) conferred susceptibility to lung cancer [8;30]. Our results support these previous reports and further suggest a role for the *BAG6* gene in the etiology of non small cell lung cancer. *BAG6* polypeptides regulates a variety of cellular processes such as apoptosis [41], HLA class II expression [42], T cell responses [43], protein modification and gene expression [44]. All these processes may require that the *BAG6* protein is constitutively expressed at steady-state levels for optimal functioning. In addition, the *BAG6* rs3117582 SNP is located at the promoter region of the *BAG6* gene (38 basepairs from the transcription start site). Mutations at the promoter region of genes have been shown to influence the expression levels of the respective genes. This may concurrently attenuate the physiological efficiency of the genes in a dose-response manner [45;46]. Our results suggest that the C allele of *BAG6* rs3117582 SNP is associated with increased risk for NSCLC in the Norwegian subjects and the combined Croatian and Norwegian subjects in a gene-dosage manner. This may also suggest that, the presence of the minor C allele of *BAG6* rs3117582 SNP in its promoter may perturbed the *BAG6* gene expression. This perturbation may lead to significant increase in NSCLC risk in individuals that bear this allele. This postulation needs to be investigated in further studies to determine and ascertain the possible underlying mechanism(s) of action.

In conclusion, our study suggests that the *FAM46A* gene VNTR and *BAG6* rs3117582 SNP are associated with NSCLC in both the Croatian and Norwegian populations. Our results also corroborate the previous findings that *BAG6* gene is associated with lung cancer and suggest gene-dosage association of the *BAG6* rs3117582 SNP with NSCLC. We further suggest that these loci could be potential research targets that might have therapeutic potentials.

## Author Contributions

Conceived and designed the experiments: GEE ZD. Performed the experiments: GEE. Analyzed the data: GEE SZ. Contributed reagents/materials/analysis tools: GEE SZ ZK ME SB VF LB AR VS PB AH ZD. Wrote the paper: GEE SZ ZK ME SB VF LB AR VS PB AH ZD.

## References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin* 2011;61:69–90. pmid:21296855

[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)

2. Spitz MR, Hong WK, Amos CI, Wu X, Schabath MB, Dong Q, et al. A risk model for prediction of lung cancer. *J Natl Cancer Inst* 2007;99:715–726. pmid:17470739  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
3. Albright F, Teerlink C, Werner TL, Cannon-Albright LA. Significant evidence for a heritable contribution to cancer predisposition: a review of cancer familiarity by site. *BMC Cancer* 2012;12:138. pmid:22471249  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
4. Brennan P, Hainaut P, Boffetta P. Genetics of lung-cancer susceptibility. *Lancet Oncol* 2011;12:399–408. pmid:20951091  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
5. Cote ML, Liu M, Bonassi S, Neri M, Schwartz AG, Christiani DC, et al. Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium. *Eur J Cancer* 2012;48:1957–1968. pmid:22436981  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
6. Dong J, Jin G, Wu C, Guo H, Zhou B, Lv J, et al. Genome-wide association study identifies a novel susceptibility locus at 12q23.1 for lung squamous cell carcinoma in han chinese. *PLoS Genet* 2013;9:e1003190. pmid:23341777  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
7. Hart K, Landvik NE, Lind H, Skaug V, Haugen A, Zienolddiny S. A combination of functional polymorphisms in the CASP8, MMP1, IL10 and SEPS1 genes affects risk of non-small cell lung cancer. *Lung Cancer* 2011;71:123–129. pmid:20471133  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
8. Rudd MF, Webb EL, Matakidou A, Sellick GS, Williams RD, Bridle H, et al. Variants in the GH-IGF axis confer susceptibility to lung cancer. *Genome Res* 2006;16:693–701. pmid:16741161  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
9. Timofeeva MN, Hung RJ, Rafnar T, Christiani DC, Field JK, Bickeboller H, et al. Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls. *Hum Mol Genet* 2012;21:4980–4995. pmid:22899653  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
10. Truong T, Sauter W, McKay JD, Hosgood HD III, Gallagher C, Amos CI, et al. coordinated association study of 10 potential lung cancer susceptibility variants. *Carcinogenesis* 2010;31:625–633. pmid:20106900  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
11. Walsh KM, Gorlov IP, Hansen HM, Wu X, Spitz MR, Zhang H, et al. Fine-mapping of the 5p15.33, 6p22.1-p21.31, and 15q25.1 regions identifies functional and histology-specific lung cancer susceptibility loci in African-Americans. *Cancer Epidemiol Biomarkers Prev* 2013;22:251–260. pmid:23221128  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
12. Azzoli CG, Park BJ, Pao W, Zakowski M, Kris MG. Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: a time for excitement and equipoise. *J Thorac Oncol* 2008;3:84–93. pmid:18166846  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
13. Jacobsen B, Kriegbaum MC, Santoni-Rugiu E, Ploug M. C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinoma. *World J Clin Oncol* 2014;5:621–632. pmid:25302166  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
14. Farhat FS, Tfayli A, Fakhruddin N, Mahfouz R, Otrock ZK, Alameddine RS, et al. Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer. *Crit Rev Oncol Hematol* 2012;84:149–160. pmid:22494932  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
15. Campbell L, Blackhall F, Thatcher N. Gefitinib for the treatment of non-small-cell lung cancer. *Expert Opin Pharmacother* 2010;11:1343–1357. pmid:20426712  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
16. Gridelli C, Maione P, Bareschino MA, Schettino C, Sacco PC, Ambrosio R, et al. Erlotinib in the treatment of non-small cell lung cancer: current status and future developments. *Anticancer Res* 2010;30:1301–1310. pmid:20530444  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
17. Hannan AJ. TRP'ing up the genome: Tandem repeat polymorphisms as dynamic sources of genetic variability in health and disease. *Discov Med* 2010;10:314–321. pmid:21034672  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
18. Hannan AJ. Tandem repeat polymorphisms: modulators of disease susceptibility and candidates for 'missing heritability'. *Trends Genet* 2010;26:59–65. pmid:20036436  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)

19. Lindstedt BA, Ryberg D, Zienolddiny S, Khan H, Haugen A. Hras1 VNTR alleles as susceptibility markers for lung cancer: relationship to microsatellite instability in tumors. *Anticancer Res* 1999;19:5523–5527. pmid:10697610  
View Article • PubMed/NCBI • Google Scholar
20. Ryberg D, Lindstedt BA, Zienolddiny S, Haugen A. A hereditary genetic marker closely associated with microsatellite instability in lung cancer. *Cancer Res* 1995;55:3996–3999. pmid:7664270  
View Article • PubMed/NCBI • Google Scholar
21. Hu Z, Shao M, Chen Y, Zhou J, Qian J, Xu L, et al. Allele 2 of the interleukin-1 receptor antagonist gene (IL1RN\*2) is associated with a decreased risk of primary lung cancer. *Cancer Lett* 2006;236:269–275. pmid:16019127  
View Article • PubMed/NCBI • Google Scholar
22. Lind H, Zienolddiny S, Ryberg D, Skaug V, Phillips DH, Haugen A. Interleukin 1 receptor antagonist gene polymorphism and risk of lung cancer: a possible interaction with polymorphisms in the interleukin 1 beta gene. *Lung Cancer* 2005;50:285–290. pmid:16126303  
View Article • PubMed/NCBI • Google Scholar
23. Liu B, Yang L, Huang B, Cheng M, Wang H, Li Y, et al. A functional copy-number variation in MAPKAPK2 predicts risk and prognosis of lung cancer. *Am J Hum Genet* 2012;91:384–390. pmid:22883146  
View Article • PubMed/NCBI • Google Scholar
24. Lagali PS, Kakuk LE, Griesinger IB, Wong PW, Ayyagari R. Identification and characterization of C6orf37, a novel candidate human retinal disease gene on chromosome 6q14. *Biochem Biophys Res Commun* 2002;293:356–365. pmid:12054608  
View Article • PubMed/NCBI • Google Scholar
25. Barragan I, Borrego S, Abd El-Aziz MM, El-Ashry MF, Abu-Safieh L, Bhattacharya SS, et al. Genetic analysis of FAM46A in Spanish families with autosomal recessive retinitis pigmentosa: characterisation of novel VNTRs. *Ann Hum Genet* 2008;72:26–34. pmid:17803723  
View Article • PubMed/NCBI • Google Scholar
26. Cui J, Wang W, Lai MD, Xu EP, Lv BJ, Lin J, et al. Identification of a novel VNTR polymorphism in C6orf37 and its association with colorectal cancer risk in Chinese population. *Clin Chim Acta* 2006;368:155–159. pmid:16545789  
View Article • PubMed/NCBI • Google Scholar
27. Kuchta K, Knizewski L, Wyrwicz LS, Rychlewski L, Ginalski K. Comprehensive classification of nucleotidyltransferase fold proteins: identification of novel families and their representatives in human. *Nucleic Acids Res* 2009;37:7701–7714. pmid:19833706  
View Article • PubMed/NCBI • Google Scholar
28. Colland F, Jacq X, Trouplin V, Mouglin C, Groizeleau C, Hamburger A, et al. Functional proteomics mapping of a human signaling pathway. *Genome Res* 2004;14:1324–1332. pmid:15231748  
View Article • PubMed/NCBI • Google Scholar
29. Lim J, Hao T, Shaw C, Patel AJ, Szabo G, Rual JF, et al. A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration. *Cell* 2006;125:801–814. pmid:16713569  
View Article • PubMed/NCBI • Google Scholar
30. Wang Y, Broderick P, Webb E, Wu X, Vijaykrishnan J, Matakidou A, et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. *Nat Genet* 2008;40:1407–1409. pmid:18978787  
View Article • PubMed/NCBI • Google Scholar
31. Wu YH, Shih SF, Lin JY. Ricin triggers apoptotic morphological changes through caspase-3 cleavage of BAT3. *J Biol Chem* 2004;279:19264–19275. pmid:14960581  
View Article • PubMed/NCBI • Google Scholar
32. Etokebe GE, Kuchler AM, Haraldsen G, Landin M, Osmundsen H, Dembic Z. Family-with-sequence-similarity-46, member A (Fam46a) gene is expressed in developing tooth buds. *Arch Oral Biol* 2009;54:1002–1007. pmid:19740458  
View Article • PubMed/NCBI • Google Scholar
33. Etokebe GE, Jotanovic Z, Mihelic R, Jericevic BM, Nikolic T, Balen S, et al. Susceptibility to large-joint osteoarthritis (hip and knee) is associated with BAG6 rs3117582 SNP and the VNTR polymorphism in the second exon of the FAM46A gene on chromosome 6. *J Orthop Res* 2014.
34. Etokebe GE, Bulat-Kardum L, Munthe LA, Balen S, Dembic Z. Association of variable number of tandem repeats in the coding region of the FAM46A gene, FAM46A rs11040 SNP and BAG6 rs3117582 SNP with susceptibility to tuberculosis. *PLoS One* 2014;9:e91385. pmid:24625963  
View Article • PubMed/NCBI • Google Scholar
35. Fan WC, Ting WY, Lee MC, Huang SF, Chiu CH, Lai SL, et al. Latent TB infection in newly diagnosed lung cancer patients—A multicenter prospective observational study. *Lung Cancer* 2014;85:472–478. pmid:25063540  
View Article • PubMed/NCBI • Google Scholar
36. Jotanovic Z, Etokebe GE, Mihelic R, Heiland KM, Mulac-Jericevic B, Tijanic T, et al. Hip osteoarthritis susceptibility is associated with IL1B -511(G>A) and IL1 RN (VNTR) genotypic polymorphisms in Croatian Caucasian population. *J Orthop Res* 2011;29:1137–1144. pmid:21671260  
View Article • PubMed/NCBI • Google Scholar



37. Jotanovic Z, Etokebe GE, Mihelic R, Kaarvatn MH, Mulac-Jericevic B, Tijanac T, et al. IL1B -511(G>A) and IL1RN (VNTR) allelic polymorphisms and susceptibility to knee osteoarthritis in Croatian population. *Rheumatol Int* 2012;32:2135–2141. PMID:21523343  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
  
38. Kaarvatn MH, Jotanovic Z, Mihelic R, Etokebe GE, Mulac-Jericevic B, Tijanac T, et al. Associations of the interleukin-1 gene locus polymorphisms with risk to hip and knee osteoarthritis: gender and subpopulation differences. *Scand J Immunol* 2013;77:151–161. PMID:23216199  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
  
39. Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL. SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. *Cell* 1998;95:779–791. PMID:9865696  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
  
40. Kawabata M, Imamura T, Inoue H, Hanai J, Nishihara A, Hanyu A, et al. Intracellular signaling of the TGF-beta superfamily by Smad proteins. *Ann N Y Acad Sci* 1999;886:73–82. PMID:10667205  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
  
41. Sasaki T, Gan EC, Wakeham A, Kornbluth S, Mak TW, Okada H. HLA-B-associated transcript 3 (Bat3)/Scythe is essential for p300-mediated acetylation of p53. *Genes Dev* 2007;21:848–861. PMID:17403783  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
  
42. Kamper N, Franken S, Temme S, Koch S, Bieber T, Koch N. gamma-Interferon-regulated chaperone governs human lymphocyte antigen class II expression. *FASEB J* 2012;26:104–116. PMID:21940994  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
  
43. Rangachari M, Zhu C, Sakuishi K, Xiao S, Karman J, Chen A, et al. Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion. *Nat Med* 2012;18:1394–1400. PMID:22863785  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
  
44. Nguyen P, Bar-Sela G, Sun L, Bisht KS, Cui H, Kohn E, et al. BAT3 and SET1A form a complex with CTCFL/BORIS to modulate H3K4 histone dimethylation and gene expression. *Mol Cell Biol* 2008;28:6720–6729. PMID:18765639  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
  
45. Aguillon JC, Cruzat A, Aravena O, Salazar L, Llanos C, Cuchacovich M. Could single-nucleotide polymorphisms (SNPs) affecting the tumour necrosis factor promoter be considered as part of rheumatoid arthritis evolution? *Immunobiology* 2006;211:75–84. PMID:16446172  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
  
46. Shih MC, Chiu YN, Hu MC, Guo IC, Chung BC. Regulation of steroid production: analysis of Cyp11a1 promoter. *Mol Cell Endocrinol* 2011;336:80–84. PMID:21195129  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)